Labeling of Nonprescription Human Drug Products Marketed w/o an Approved App as Required by the Dietary Supp & Nonpresription Drug Consumer Protection Act
Labeling of Nonprescription
Human Drug Products Marketed w/o an Approved App as Required by the
Dietary Supp & Nonpresription Drug Consumer Protection Act
Extension without change of a currently approved collection
This information collection supports
implementation of the Dietary Supplement and Nonprescription Drug
Consumer Protection Act (DSNDCPA) (Pub. L. 109-462). The Public Law
added section 502(x) to the Federal Food, Drug, and Cosmetic Act
(the FD&C Act) (21 U.S.C. 352(x)), requiring the label of a
nonprescription drug product marketed without an approved
application in the United States to include a domestic address or
domestic telephone number through which a manufacturer, packer, and
distributor may receive a report of a serious adverse event
associated with its product(s).
PL:
Pub.L. 109 - 462 760 Name of Law: Dietary Supplement and
Nonprescription Drug Consumer Protection Act
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.